Patents by Inventor Sylvie TISSOT

Sylvie TISSOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS
    Patent number: 9110079
    Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 18, 2015
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON (HCL)
    Inventors: Marie-Angélique Cazalis, Alexandre Pachot, Sylvie Tissot, Guillaume Monneret
  • METHOD AND KIT FOR ESTABLISHING AN IN VITRO PROGNOSIS ON A PATIENT EXHIBITING SIRS
    Publication number: 20120077693
    Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 29, 2012
    Applicants: HOSPICES CIVILS DE LYON (HCL), BIOMERIEUX
    Inventors: Marie-Angélique CAZALIS, Alexandre PACHOT, Sylvie TISSOT, Guillaume MONNERET